Clinical Trial Results: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) [Phase 2]

View source ↗

Summary

Phase 2 trial results of Brexucabtagene Autoleucel (KTE-X19) show outcomes in relapsed/refractory mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Brexucabtagene Autoleucel (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2026-08-18